NASDAQ:LNSR LENSAR (LNSR) Stock Price, News & Analysis $12.71 +0.33 (+2.67%) Closing price 04:00 PM EasternExtended Trading$12.70 -0.01 (-0.08%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LENSAR Stock (NASDAQ:LNSR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LENSAR alerts:Sign Up Key Stats Today's Range$12.29▼$12.7850-Day Range$12.04▼$13.3252-Week Range$4.20▼$17.31Volume75,508 shsAverage Volume67,354 shsMarket Capitalization$151.76 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingHold Company Overview LENSAR, Inc., headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions. Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment. The company holds multiple patents related to its image-guided treatment planning and laser control algorithms. Clinical collaborations and peer-reviewed studies have supported the safety and efficacy of the LENSAR system, demonstrating improvements in procedural consistency and efficiency. Operating across North America, Europe, the Asia-Pacific region and Latin America, LENSAR markets its laser platforms to hospitals, ambulatory surgery centers and specialty eye clinics. The company offers comprehensive training programs for ophthalmic surgeons, ongoing technical support and regular software upgrades to help practices integrate femtosecond laser technology. By maintaining a focused portfolio of ophthalmic solutions, LENSAR seeks to advance the standard of care in cataract surgery through continuous innovation and service excellence.AI Generated. May Contain Errors. Read More LENSAR Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreLNSR MarketRank™: LENSAR scored higher than 15% of companies evaluated by MarketBeat, and ranked 797th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingHold Consensus RatingLENSAR has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialLENSAR has a consensus price target of $15.00, representing about 18.0% upside from its current price of $12.71.Amount of Analyst CoverageLENSAR has received no research coverage in the past 90 days.Read more about LENSAR's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of LENSAR is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENSAR is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENSAR has a P/B Ratio of 30.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about LENSAR's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.51% of the float of LENSAR has been sold short.Short Interest Ratio / Days to CoverLENSAR has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in LENSAR has recently increased by 0.87%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENSAR does not currently pay a dividend.Dividend GrowthLENSAR does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.51% of the float of LENSAR has been sold short.Short Interest Ratio / Days to CoverLENSAR has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in LENSAR has recently increased by 0.87%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for LENSAR this week, compared to 1 article on an average week.MarketBeat Follows1 people have added LENSAR to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENSAR insiders have not sold or bought any company stock.Percentage Held by Insiders66.00% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENSAR's insider trading history. Receive LNSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LNSR Stock News HeadlinesFinancial Contrast: LENSAR (NASDAQ:LNSR) versus TransMedics Group (NASDAQ:TMDX)September 22 at 3:01 AM | americanbankingnews.comLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he’s kneecapped the Federal Reserve…September 22 at 2:00 AM | Banyan Hill Publishing (Ad)Lensar (LNSR) Q2 Revenue Rises 10%August 15, 2025 | theglobeandmail.comLENSAR Reports Second Quarter 2025 Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comLENSAR, Inc. Grants 660 Restricted Stock Units to New Non-Executive Employees as Inducement for Employment - NasdaqJuly 3, 2025 | nasdaq.comLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comSee More Headlines LNSR Stock Analysis - Frequently Asked Questions How have LNSR shares performed this year? LENSAR's stock was trading at $8.94 at the beginning of 2025. Since then, LNSR shares have increased by 42.2% and is now trading at $12.71. How were LENSAR's earnings last quarter? LENSAR, Inc. (NASDAQ:LNSR) announced its earnings results on Thursday, August, 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.08. The company had revenue of $11.36 million for the quarter, compared to analyst estimates of $16.55 million. LENSAR had a negative net margin of 84.49% and a negative trailing twelve-month return on equity of 737.30%. Who are LENSAR's major shareholders? LENSAR's top institutional shareholders include Brandes Investment Partners LP (4.72%), Groupe la Francaise (2.11%), Geode Capital Management LLC (1.86%) and Credit Industriel ET Commercial (1.43%). Insiders that own company stock include Thomas R Staab II and Gary M Winer. View institutional ownership trends. How do I buy shares of LENSAR? Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LENSAR own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENSAR investors own include Arch Capital Group (ACGL), Aprea Therapeutics (APRE), Artelo Biosciences (ARTL), AstraZeneca (AZN), Baidu (BIDU), Cidara Therapeutics (CDTX) and Carlyle Group (CG). Company Calendar Last Earnings8/07/2025Today9/22/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LNSR CIK1320350 Webwww.lensar.com Phone888-536-7271FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for LENSAR$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+18.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.40 million Net Margins-84.49% Pretax Margin-84.49% Return on Equity-737.30% Return on Assets-72.60% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio0.88 Sales & Book Value Annual Sales$58.36 million Price / Sales2.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book30.26Miscellaneous Outstanding Shares11,935,000Free Float4,058,000Market Cap$151.69 million OptionableOptionable Beta0.49 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:LNSR) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredThe next AI Hype Spike is days away — don’t miss itOn this date, AI could trigger the kind of predictable surge that's already paid out 61%… 158%… and even 382% ...Brownstone Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.